Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds

PHASE4CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

February 29, 2012

Conditions
Wrinkles
Interventions
DRUG

onabotulinumtoxinA

"* Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~* Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment."

DRUG

JUVÉDERM

"Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~• Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment."

Trial Locations (3)

80113

About Skin Dermatology, Englewood

L2E 7H1

Niagara Falls Dermantology and Skin Care Center, Niagara Falls

M5R3N8

University of Toronto, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

AboutSkin Dermatology and DermSurgery, PC

INDUSTRY